Stephen Campe - Neuronetics Independent Director
| STIM Stock | USD 3.81 0.31 8.86% |
Director
Mr. Stephen M. Campe is Independent Director of the company since 2013. Mr. Campe is Senior Advisor to Patricia Industries, Inc., or Patricia, a whollyowned private equity and VC subsidiary of Investor AB. Mr. Campe joined Investor AB in 1998 as Managing Director and head of the healthcare investing team, and served as President of a predecessor entity to Patricia from 2008 to 2015 with responsibility for Investor ABs global VC activities. Mr. Campe was an active healthcare investor for over 20 years, focusing his investing activities primarily on medical technology including therapeutic, surgical, and diagnostic devices. Previously, Mr. Campe was a consultant at McKinsey Company where he managed corporate finance and strategy engagements for several diversified healthcare companies, and was an investment banker specializing in mergers and acquisitions since 2013.
| Age | 53 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 3222 Phoenixville Pike, Malvern, PA, United States, 19355 |
| Phone | 610 640 4202 |
| Web | https://neurostar.com |
Neuronetics Management Efficiency
The company has return on total asset (ROA) of (0.1534) % which means that it has lost $0.1534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6617) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of May 2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Neuronetics' Net Tangible Assets are very stable compared to the past year. As of the 4th of May 2024, Other Current Assets is likely to grow to about 7.6 M, while Non Current Assets Total are likely to drop about 13.4 M.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| Dieter Schapfel | Enzo Biochem | 57 | |
| Dov Perlysky | Enzo Biochem | 58 | |
| MS MD | Sera Prognostics | 71 | |
| Mary Tagliaferri | Enzo Biochem | 53 | |
| Bruce Hanna | Enzo Biochem | 75 | |
| Tina Nova | Exagen Inc | 70 | |
| Brian Gavin | Burning Rock BiotechLtd | N/A | |
| Michael Byron | Burning Rock BiotechLtd | 55 | |
| Gregory Bortz | Enzo Biochem | 48 | |
| Ian Walters | Enzo Biochem | 52 | |
| Bernard Kasten | Enzo Biochem | 68 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.15 |
Neuronetics Leadership Team
Elected by the shareholders, the Neuronetics' board of directors comprises two types of representatives: Neuronetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuronetics. The board's role is to monitor Neuronetics' management team and ensure that shareholders' interests are well served. Neuronetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuronetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Pui, Vice President of International Commercial Development | ||
| Mark Klausner, Managing Partner | ||
| Stephen Campe, Independent Director | ||
| Rick Grubbs, Senior Accounts | ||
| Christopher Thatcher, President CEO, Director | ||
| Kara Thornton, VP Director | ||
| Glenn Muir, Independent Director | ||
| Keith Sullivan, CEO President | ||
| Rusty Page, Senior Quality | ||
| Steve MacKinnon, Vice President - Sales | ||
| Mark Bausinger, CFO | ||
| Stephen MS, CFO VP | ||
| Chris Thatcher, President CEO, Director | ||
| Lisa MetznerRosas, Senior Officer | ||
| Andrew Macan, Gen VP | ||
| Claire Sears, VP Marketing | ||
| Peter Donato, CFO, Vice President | ||
| Cory Anderson, Senior Clinical | ||
| Wilfred Jaeger, Independent Director | ||
| Daniel Guthrie, Chief Commercial Officer | ||
| Mark Demitrack, Chief Medical Officer | ||
| Stephen Furlong, CFO, Secretary | ||
| Ronald Hunt, Independent Director | ||
| Brian Farley, Independent Chairman of the Board | ||
| Yelena Tropsha, Vice President - Commercial Access | ||
| Gregory Harper, Vice President of Research and Development, Operations and Product Development | ||
| Sara Grubbs, Senior Officer | ||
| Cheryl Blanchard, Independent Director |
Neuronetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuronetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 106.94 M | ||||
| Shares Outstanding | 29.97 M | ||||
| Shares Owned By Insiders | 6.31 % | ||||
| Shares Owned By Institutions | 65.13 % | ||||
| Number Of Shares Shorted | 57.69 K | ||||
| Price To Book | 3.76 X |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Neuronetics Stock analysis
When running Neuronetics' price analysis, check to measure Neuronetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuronetics is operating at the current time. Most of Neuronetics' value examination focuses on studying past and present price action to predict the probability of Neuronetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuronetics' price. Additionally, you may evaluate how the addition of Neuronetics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Neuronetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 2.49 | Quarterly Revenue Growth 0.116 | Return On Assets (0.15) | Return On Equity (0.66) |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.